Amneal Pharmaceuticals Debt to Equity

Amneal Pharmaceuticals (AMRX) currently reports a debt-to-equity ratio of 84.54. That is above the Healthcare sector average of 0.3. Use the charts on this page to explore Amneal Pharmaceuticals's debt-to-equity ratio history and peer comparisons.

Amneal Pharmaceuticals's debt-to-equity ratio of 84.54 is higher than the Healthcare sector average of 0.3. That is roughly 28417.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Amneal Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 84.54, AMRX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 84.54, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.3. From there, open related valuation or income-statement pages for Amneal Pharmaceuticals, and consider following AMRX for alerts when major investors trade the stock.

Amneal Pharmaceuticals is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows 84.54 versus a sector average near 0.3. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMRX with unrelated industries.